SCHEMBL4297483

SCHEMBL4297483

Cc1cc(C(=O)Nc2nccs2)cc(Cl)c1N

nearest known ligand 0.62

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ADORA2A P29274 3/20 0.62
ADORA1 P30542 3/20 0.62
RAB9A P51151 9/20 0.56
NPC1 O15118 8/20 0.56
SMN1; SMN2 Q16637 5/20 0.56
LMNA P02545 2/20 0.56
L3MBTL1 Q9Y468 2/20 0.56
PPARG P37231 1/20 0.56
NCOR2 Q9Y618 1/20 0.56
RECQL P46063 1/20 0.56
MAPT P10636 3/20 0.53
BRD4 O60885 1/20 0.53
GCK P35557 1/20 0.52
MAPK1 P28482 2/20 0.52
PIK3CD O00329 1/20 0.52
PIK3C2B O00750 1/20 0.52
AURKA O14965 1/20 0.52
PIK3C2G O75747 1/20 0.52
CDK1 P06493 1/20 0.52
CDK4 P11802 1/20 0.52

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4299674 0.91 RAB9A (0.62) ADORA2AADORA1RAB9ANPC1SMN1; SMN2
SCHEMBL4289701 0.81 NPC1 (0.52) ADORA2AADORA1RAB9ANPC1SMN1; SMN2
SCHEMBL3900518 0.81 RAB9A (0.64) ADORA2AADORA1RAB9ANPC1SMN1; SMN2
SCHEMBL3190864 0.79 RAB9A (0.66) ADORA2AADORA1RAB9ANPC1SMN1; SMN2
SCHEMBL3200155 0.79 RAB9A (0.66) ADORA2AADORA1RAB9ANPC1SMN1; SMN2
SCHEMBL14018616 0.78 RAB9A (0.72) RAB9ANPC1SMN1; SMN2LMNAL3MBTL1
SCHEMBL8797071 0.78 NPC1 (0.62) RAB9ANPC1SMN1; SMN2LMNAL3MBTL1
SCHEMBL4290840 0.77 ADORA2A (1.00) ADORA2AADORA1RAB9ANPC1SMN1; SMN2
SCHEMBL4297087 0.77 MAPK1 (0.61) ADORA2AADORA1RAB9ANPC1SMN1; SMN2
SCHEMBL1119373 0.77 RAB9A (0.71) ADORA2AADORA1RAB9ANPC1SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090247593-A1 N-THIAZOL-2-YL-BENZAMIDE DERIVATIVES H. LUNDBECK A/S (DK) 2009-10-01 US disclosed
EP-1803455-A1 N-thiazol-2-yl-benzamide derivatives H.Lundbeck A/S (DK) 2007-07-04 EP disclosed
EP-1682129-B1 N-THIAZOL-2-YL-BENZAMIDE DERIVATIVES LUNDBECK & CO AS H (DK) 2007-02-21 EP disclosed
CN-1870996-A N-thiazol-2-yl-benzamide derivatives LUNDBECK & CO AS H (DK) 2006-11-29 CN disclosed
EP-1682129-A1 N-THIAZOL-2-YL-BENZAMIDE DERIVATIVES H. LUNDBECK A/S (DK) 2006-07-26 EP disclosed
US-20060154974-A1 N-thiazol-2-yl-benzamide derivatives H. LUNDBECK A/S (DK) 2006-07-13 US disclosed
WO-2005039572-A1 N-THIAZOL-2-YL-BENZAMIDE DERIVATIVES H. LUNDBECK A/S (DK) 2005-05-06 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090247593-A1 N-THIAZOL-2-YL-BENZAMIDE DERIVATIVES ADORA2A, ADORA3, ADORA1 ADORA2A 1/4885ADORA1 3/4885RAB9A 2380/4885
US-20060154974-A1 N-thiazol-2-yl-benzamide derivatives ADORA2A, ADORA3, ADORA1 ADORA2A 1/4885ADORA1 3/4885RAB9A 2380/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.